22029-01-2

Basic information

• Product Name: L-Proline, 4-hydroxy-1-[N-[(phenylmethoxy)carbonyl]glycyl]-
• CAS NO: 22029-01-2
• Molecular Formula: C15H18N2O6
• Molecular Weight: 322.318
• Mol File: 22029-01-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: L-Proline, 4-hydroxy-1-[N-[(phenylmethoxy)carbonyl]glycyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: L-Proline, 4-hydroxy-1-[N-[(phenylmethoxy)carbonyl]glycyl]-(22029-01-2)
• EPA Substance Registry System: L-Proline, 4-hydroxy-1-[N-[(phenylmethoxy)carbonyl]glycyl]-(22029-01-2)

Safety Data

• Hazardous Substances Data: 22029-01-2(Hazardous Substances Data)

Upstream product

• 2899-60-7 Cbz-Gly-ONSuc 
• 51-35-4 4R-4-hydroxyproline 
• 1138-80-3 N-(Benzyloxycarbonyl)glycine 
• 15050-24-5 N-(benzyloxycarbonyl)glycyl chloride 
• 440678-43-3 cis-4-hydroxy-L-prolin-ethyl ester 

Downstream Products

• 516526-75-3 N-(N-benzyloxycarbonylglycyl)-4-oxo-L-proline methyl ester 
• 516526-74-2 N-(N-benzyloxycarbonylglycyl)-4-oxo-L-proline tert-butyl ester 
• 516526-77-5 N-(N-benzyloxycarbonylglycyl)-4-cis-(methoxycarbonylmethyl)acetamido-L-proline tert-butyl ester 
• 516526-86-6 N-(N-benzyloxycarbonylglycyl)-4-trans-benzyloxycarbonylmethylamino-L-proline 
• 516526-85-5 N-(N-benzyloxycarbonylglycyl)-4-cis-benzyloxycarbonylmethylamino-L-proline methyl ester 
• 516526-84-4 (2S,4S)-4-(Acetyl-carboxymethyl-amino)-1-(2-benzyloxycarbonylamino-acetyl)-pyrrolidine-2-carboxylic acid tert-butyl ester 
• 516526-83-3 N-(N-benzyloxycarbonylglycyl)-cis-4-(benzyloxycarbonylmethyl)acetamido-L-proline tert-butyl ester 
• 915958-47-3 C₃₄H₃₇N₃O₉ 
• 915958-47-3 C₃₄H₃₇N₃O₉ 
• 516526-73-1 N-(N-benzyloxycarbonylglycyl)-4-oxo-L-proline 
• 516526-78-6 N-(N-benzyloxycarbonylglycyl)-4-hydroxy-L-proline methyl ester 
• 24587-32-4 cis-1-glycyl-4-hydroxy-L-proline 
• 24587-32-4 trans-1-glycyl-4-hydroxy-L-proline 

Relevant articles and documents

ANALOGS OF GLYCYL-PROLYL-GLUTAMATE

Embodiments of this invention include novel analogs of Glycyl-Prolyl-Glutamate (GPE) and compositions containing such analogs of GPE. Of these, certain analogs have modified proline residues. Other embodiments of this invention include uses of analogs of GPE to protect neural cells from degeneration and/or death in response to injury or disease. Disorders treatable with compounds and compositions of this invention include hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson''s disease.